Theravance Biopharma Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.

It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).

Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).

It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.

Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Theravance Biopharma, Inc.

Country	Cayman Islands
Founded	2013
Industry	Pharmaceutical Preparations
Employees	97
CEO	Rick Winningham

Contact Details

Address: 901 Gateway Boulevard South San Francisco, 94080 United States
Phone	650 808 6000
Website	theravance.com

Stock Details

Ticker Symbol	0TB
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Rick Winningham	Chief Executive Officer
Aziz Sawaf	Chief Financial Officer